Duchenne Muscular Dystrophy - Pipeline Review, H2 2016

Date: August 10, 2016
Pages: 283
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D8615C14ED7EN
Leaflet:

Download PDF Leaflet

Duchenne Muscular Dystrophy - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Duchenne Muscular Dystrophy - Pipeline Review, H2 2016’, provides an overview of the Duchenne Muscular Dystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy
  • The report reviews pipeline therapeutics for Duchenne Muscular Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Duchenne Muscular Dystrophy therapeutics and enlists all their major and minor projects
  • The report assesses Duchenne Muscular Dystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Duchenne Muscular Dystrophy Overview
Therapeutics Development
Pipeline Products for Duchenne Muscular Dystrophy - Overview
Pipeline Products for Duchenne Muscular Dystrophy - Comparative Analysis
Duchenne Muscular Dystrophy - Therapeutics under Development by Companies
Duchenne Muscular Dystrophy - Therapeutics under Investigation by Universities/Institutes
Duchenne Muscular Dystrophy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Duchenne Muscular Dystrophy - Products under Development by Companies
Duchenne Muscular Dystrophy - Products under Investigation by Universities/Institutes
Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
Anagenesis Biotechnology
Asklepios BioPharmaceutical, Inc.
BioMarin Pharmaceutical Inc.
Bristol-Myers Squibb Company
Capricor Therapeutics, Inc.
Catabasis Pharmaceuticals, Inc.
Daiichi Sankyo Company, Limited
Debiopharm International SA
Editas Medicine, Inc.
EryDel SPA
FibroGen, Inc.
Galapagos NV
Genethon
GTx, Inc.
GW Pharmaceuticals Plc
Idera Pharmaceuticals, Inc.
Italfarmaco S.p.A.
La Jolla Pharmaceutical Company
Lexicon Pharmaceuticals, Inc.
Marathon Pharmaceuticals, LLC
Marina Biotech, Inc.
Merck KGaA
Milo Biotechnology LLC
Mitochon Pharmaceuticals, Inc.
MyoTherix Inc.
NicOx S.A.
Nippon Shinyaku Co., Ltd.
Nobelpharma Co., Ltd.
Pfizer Inc.
Pluristem Therapeutics Inc.
Prothelia, Inc.
PTC Therapeutics, Inc.
RASRx, LLC
ReveraGen BioPharma, Inc.
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics, Inc.
Summit Therapeutics Plc
Taiho Pharmaceutical Co., Ltd.
WAVE Life Sciences Ltd.
Zambon Company S.p.A.
Duchenne Muscular Dystrophy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
4-P001 - DRUG PROFILE
AAV1-Foliistatin - Drug Profile
ACE-083 - Drug Profile
alisporivir - Drug Profile
Antisense Oligonucleotide 1 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile
Antisense Oligonucleotides to Inhibit ACVR2B for Duchenne Muscular Dystrophy - Drug Profile
Antisense RNAi Oligonucleotides for Duchenne Muscular Dystrophy - Drug Profile
Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile
arbekacin - Drug Profile
ARM-210 - Drug Profile
AT-300 - Drug Profile
ataluren - Drug Profile
Biostrophin - Drug Profile
BMBD-001 - Drug Profile
BMS-986089 - Drug Profile
CAP-1002 - Drug Profile
CAP-2003 - Drug Profile
CAT-1004 - Drug Profile
DA-4210 - Drug Profile
deflazacort - Drug Profile
dexamethasone sodium phosphate - Drug Profile
domagrozumab - Drug Profile
Drug for Duchenne Muscular Dystrophy - Drug Profile
Drugs for Duchenne Muscular Dystrophy - Drug Profile
DS-5141 - Drug Profile
DT-200 - Drug Profile
enobosarm - Drug Profile
eteplirsen - Drug Profile
ezutromid - Drug Profile
Gene Therapy for Duchenne Muscular Dystrophy - Drug Profile
Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies - Drug Profile
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Gene Therapy to Activate Utrophin for Duchenne Muscular Dystrophy - Drug Profile
givinostat - Drug Profile
Gtx-027 - Drug Profile
IB-DMD - Drug Profile
idebenone - Drug Profile
IMO-8400 - Drug Profile
LJPC-30Sa - Drug Profile
LJPC-30Sb - Drug Profile
LX-2931 - Drug Profile
MG-53 - Drug Profile
MP-101 - Drug Profile
Myomir - Drug Profile
naproxcinod - Drug Profile
NS-065 - Drug Profile
Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Oligonucleotides 1 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Oligonucleotides 2 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Oligonucleotides 3 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
OSX-200 - Drug Profile
pamrevlumab - Drug Profile
PLX-PAD - Drug Profile
poloxamer - Drug Profile
PRO-052 - Drug Profile
PRO-055 - Drug Profile
PRT-01 - Drug Profile
Recombinant Protein for Muscular Dystrophy - Drug Profile
Recombinant Protein to Activate Utrophin for Muscular Dystrophies - Drug Profile
Recombinant Proteins for Duchenne Muscular Dystrophy - Drug Profile
rimeporide - Drug Profile
RTC-13 - Drug Profile
SB-001 - Drug Profile
SB-002 - Drug Profile
SGT-001 - Drug Profile
Small Molecule to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Small Molecules for Duchenne Muscular Dystrophy - Drug Profile
Small Molecules for Duchenne Muscular Dystrophy - Drug Profile
Small Molecules to Activate Utrophin for Duchenne Muscular Dystrophy - Drug Profile
Small Molecules to Agonize Cannabinoid Receptor for Duchenne Muscular Dystrophy - Drug Profile
SMT-022357 - Drug Profile
SRP-4008 - Drug Profile
SRP-4044 - Drug Profile
SRP-4045 - Drug Profile
SRP-4050 - Drug Profile
SRP-4052 - Drug Profile
SRP-4053 - Drug Profile
SRP-4055 - Drug Profile
Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Stryka-516 - Drug Profile
Stryka-969 - Drug Profile
StrykaPro-1 - Drug Profile
Synthetic Peptides for Duchene Muscle Dystrophy - Drug Profile
TAS-205 - Drug Profile
TVN-102 - Drug Profile
TXA-127 - Drug Profile
vamorolone - Drug Profile
ZP-049 - Drug Profile
Duchenne Muscular Dystrophy - Dormant Projects
Duchenne Muscular Dystrophy - Discontinued Products
Duchenne Muscular Dystrophy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Duchenne Muscular Dystrophy, H2 2016
Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Development by Companies, H2 2016 (Contd.2)
Number of Products under Development by Companies, H2 2016 (Contd.3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Development by Companies, H2 2016 (Contd.2)
Products under Development by Companies, H2 2016 (Contd.3)
Products under Development by Companies, H2 2016 (Contd.4)
Products under Investigation by Universities/Institutes, H2 2016
Duchenne Muscular Dystrophy - Pipeline by Acceleron Pharma, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Anagenesis Biotechnology, H2 2016
Duchenne Muscular Dystrophy - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by BioMarin Pharmaceutical Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Bristol-Myers Squibb Company, H2 2016
Duchenne Muscular Dystrophy - Pipeline by Capricor Therapeutics, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Duchenne Muscular Dystrophy - Pipeline by Debiopharm International SA, H2 2016
Duchenne Muscular Dystrophy - Pipeline by Editas Medicine, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by EryDel SPA, H2 2016
Duchenne Muscular Dystrophy - Pipeline by FibroGen, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H2 2016
Duchenne Muscular Dystrophy - Pipeline by Genethon, H2 2016
Duchenne Muscular Dystrophy - Pipeline by GTx, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by GW Pharmaceuticals Plc, H2 2016
Duchenne Muscular Dystrophy - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Italfarmaco S.p.A., H2 2016
Duchenne Muscular Dystrophy - Pipeline by La Jolla Pharmaceutical Company, H2 2016
Duchenne Muscular Dystrophy - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Marathon Pharmaceuticals, LLC, H2 2016
Duchenne Muscular Dystrophy - Pipeline by Marina Biotech, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Merck KGaA, H2 2016
Duchenne Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H2 2016
Duchenne Muscular Dystrophy - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by MyoTherix Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by NicOx S.A., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Nobelpharma Co., Ltd., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Pfizer Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Pluristem Therapeutics Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Prothelia, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by PTC Therapeutics, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by RASRx, LLC, H2 2016
Duchenne Muscular Dystrophy - Pipeline by ReveraGen BioPharma, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2016
Duchenne Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Summit Therapeutics Plc, H2 2016
Duchenne Muscular Dystrophy - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
Duchenne Muscular Dystrophy - Pipeline by WAVE Life Sciences Ltd., H2 2016
Duchenne Muscular Dystrophy - Pipeline by Zambon Company S.p.A., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Duchenne Muscular Dystrophy - Dormant Projects, H2 2016
Duchenne Muscular Dystrophy - Dormant Projects (Contd.1), H2 2016
Duchenne Muscular Dystrophy - Dormant Projects (Contd.2), H2 2016
Duchenne Muscular Dystrophy - Dormant Projects (Contd.3), H2 2016
Duchenne Muscular Dystrophy - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Duchenne Muscular Dystrophy, H2 2016
Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

Acceleron Pharma, Inc.
Anagenesis Biotechnology
Asklepios BioPharmaceutical, Inc.
BioMarin Pharmaceutical Inc.
Bristol-Myers Squibb Company
Capricor Therapeutics, Inc.
Catabasis Pharmaceuticals, Inc.
Daiichi Sankyo Company, Limited
Debiopharm International SA
Editas Medicine, Inc.
EryDel SPA
FibroGen, Inc.
Galapagos NV
Genethon
GTx, Inc.
GW Pharmaceuticals Plc
Idera Pharmaceuticals, Inc.
Italfarmaco S.p.A.
La Jolla Pharmaceutical Company
Lexicon Pharmaceuticals, Inc.
Marathon Pharmaceuticals, LLC
Marina Biotech, Inc.
Merck KGaA
Milo Biotechnology LLC
Mitochon Pharmaceuticals, Inc.
MyoTherix Inc.
NicOx S.A.
Nippon Shinyaku Co., Ltd.
Nobelpharma Co., Ltd.
Pfizer Inc.
Pluristem Therapeutics Inc.
Prothelia, Inc.
PTC Therapeutics, Inc.
RASRx, LLC
ReveraGen BioPharma, Inc.
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics, Inc.
Summit Therapeutics Plc
Taiho Pharmaceutical Co., Ltd.
WAVE Life Sciences Ltd.
Zambon Company S.p.A.
Skip to top


Duchenne Muscular Dystrophy - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Muscular Dystrophy - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 135 pages
Becker Muscular Dystrophy - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 46 pages
Becker Muscular Dystrophy - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 48 pages

Ask Your Question

Duchenne Muscular Dystrophy - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: